Tranexamic acid in trauma: how should we use it?

Area of Science:

• Trauma care
• Pharmacology
• Hemorrhage control

Background:

• Tranexamic acid (TXA) inhibits fibrinolysis, reducing blood loss and transfusion needs in surgical settings.
• The CRASH-2 trial demonstrated TXA's efficacy in reducing mortality in bleeding trauma patients.

Purpose of the Study:

• To evaluate the safety and efficacy of tranexamic acid in managing bleeding trauma.
• To determine the optimal timing and patient population for TXA administration.

Main Methods:

• Multi-center, randomized, placebo-controlled trial (CRASH-2 trial).
• TXA administered as a 1g loading dose followed by an 8-hour infusion.
• Treatment initiated within 3 hours of traumatic injury.

Main Results:

• TXA significantly reduces the risk of hemorrhage death by approximately one-third.
• Treatment is safe and effective across a wide spectrum of bleeding trauma patients.
• Early initiation of TXA is crucial for maximizing mortality benefit.

Conclusions:

• Tranexamic acid is a vital intervention for bleeding trauma, preventing thousands of avoidable deaths.
• Widespread administration, not limited by injury severity or hyperfibrinolysis diagnosis, is recommended.
• Ongoing research (CRASH-3 trial) is exploring TXA's role in traumatic brain injury.